将人类细胞图谱医学化用于肌肉骨骼疾病:迈向转化路线图
本文综述单细胞、单核、空间和多组学方法在肌肉骨骼组织从发育到衰老、从健康到疾病绘图中的进展,涵盖胚胎骨骼发育、骨髓、肌肉衰老、骨关节炎、类风湿关节炎、肌腱病和炎症性纤维化等示例。作者提出应将肌肉骨骼人类细胞图谱(MSK-HCA)医学化,连接组织图谱与临床表型、影像、生物样本、遗传风险、生物标志物、扰动实验和干预试验,并给出转化路线图。
要点
- MSK-HCA应从被动参考目录转为连接临床表型与多组学数据的医学化平台。
- 相同诊断标签如类风湿关节炎可隐藏不同细胞机制与治疗脆弱性。
- 不同疾病如肌腱病与纤维化关节囊炎可共享趋同的基质、免疫、血管或神经程序。
核心结论
- 将HCA医学化可使细胞医学成为精准风湿病学和再生肌肉骨骼治疗的实际基础。
研究设计与样本
- 本文为综述,描述单细胞、单核、空间和多组学方法如何绘制肌肉骨骼组织从发育到衰老及从健康到疾病的图谱。
- 综述涵盖胚胎骨骼发育、骨髓、肌肉衰老、骨关节炎、类风湿关节炎、肌腱病和炎症性纤维化等示例。
主要发现
- 同一诊断标签如类风湿关节炎可掩盖不同的细胞机制、组织生态位和治疗脆弱性。
- 看似不同的疾病如肌腱病或纤维化关节囊炎可共享趋同的基质、免疫、血管或神经程序。
- 图谱数据可将疾病分类重新围绕致病性细胞状态而非仅器官层面标签。
关键数值与推荐
- MSK-HCA应设计为连接组织图谱与临床表型、影像、生物样本、遗传风险、生物标志物、扰动实验和干预试验。
- 转化路线图包括:图谱定义健康参考坐标、识别疾病富集细胞状态、提名生物标志物和治疗靶点、从临床试验结果中学习。
临床怎么用
- 临床医生可利用MSK-HCA进行机制导向的诊断和患者分层。
- 科学家可获得共享坐标系统以检验基因、细胞和组织微环境如何产生疾病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Human Cell Atlas (HCA) has fundamentally changed the way biologists describe human tissues. However, its greatest promise for musculoskeletal (MSK) practitioners lies ahead: to convert cellular maps into clinically actionable knowledge. MSK diseases are common, heterogeneous, and often insufficiently stratified by current diagnostic labels. The same label, such as rheumatoid arthritis, can conceal distinct cellular mechanisms, tissue niches, and therapeutic vulnerabilities. Conversely, apparently different disorders such as tendinopathy or fibrotic capsulitis can share convergent stromal, immune, vascular, or neuronal programmes. A MSK-HCA therefore should not be conceived as a passive reference catalogue. It should be 'medicalised': designed from the outset to connect tissue atlases with clinical phenotypes, imaging, biospecimens, genetic risk, biomarkers, perturbation experiments, and interventional trials. In this review, we describe how single-cell, single-nucleus, spatial, and multiomic approaches are beginning to map MSK tissues from development to ageing and from health to disease. We highlight examples in embryonic skeletal development, bone marrow, muscle ageing, osteoarthritis, rheumatoid arthritis, tendon disease, and inflammatory fibrosis and show how these data can reframe disease taxonomy around pathogenic cell states rather than organ-level labels alone. We propose a translational roadmap in which atlases define healthy reference coordinates, identify disease-enriched cell states, nominate biomarkers and therapeutic targets, and then learn from clinical trial outcomes. For clinicians, the MSK-HCA offers a route to mechanism-led diagnosis and patient stratification; for scientists, it provides a shared coordinate system for testing how genes, cells, and tissue microenvironments generate disease. Medicalising the HCA could make cellular medicine a practical foundation for precision rheumatology and regenerative MSK therapy.
引用
- Hourston GJM, To K, Teichmann SA, et al. Medicalising the Human Cell Atlas for musculoskeletal disease: towards a translational roadmap. Ann Rheum Dis. 2026. PMID: 42934004. doi:10.1016/j.ard.2026.09.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。